LAKE ZURICH, Ill., February 9, 2016 – Fresenius Kabi USA announced today that Seema Kumbhat, M.D., has joined the company as senior vice president and medical director. Dr. Kumbhat reports to John Ducker, president and CEO of Fresenius Kabi USA, and is a new member of the company’s executive committee.
Dr. Kumbhat and her team will be responsible for pre-and post-launch clinical and medical strategies; clinically focused training and education and scientific exchange with stakeholders in the medical community.
“Seema is a highly regarded physician executive and we are extremely pleased to have her join our leadership team,” Ducker said. “This is an important new role for Fresenius Kabi in the U.S. as we expand our business with more clinically differentiated products and services in both our pharmaceutical and medical devices businesses.”
Fresenius Kabi announced in January it acquired the BD Rx business from Becton Dickinson and Company, bringing prefilled ready-to-administer syringes and product pipeline to its growing U.S. portfolio.
Dr. Kumbhat has more than 20 years of experience in health care. Before joining Fresenius Kabi, she held similar roles of increasing responsibility at Hospira, where she was global medical director, biosimilars, in clinical development and medical affairs and medical director, device development. She has also held medical affairs roles at McKesson Provider Technologies, GE Healthcare and Epic Systems Corporation.
Dr. Kumbhat is a member of the Chicago Medical Informatics Organization, Chicago Innovation Mentors and the Chicago Council on Global Affairs. She has served as program chair of BIO’s Personalized Medicine and Diagnostics Group.
Kumbhat earned her medical degree with research distinction in surgery at the University of Miami School of Medicine and her residency in surgery was at the University of Wisconsin Hospitals and Clinics. Dr. Kumbhat earned a bachelor’s degree in biochemistry from the University of Miami, where she graduated magna cum laude.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.